Pipeline

Sensei is developing a pipeline of investigational medicines that alter the relationship between host immune cells and cancer so that the immune system recognizes tumors as a threat and unleashes an immune response.

TMAb™ Programs

The TMAb platform enables highly selective targeting of immune cells in the tumor microenvironment without on-target off-tumor activity.

Program
Target
Indication
Discovery
Preclinical
Phase I
Phase II

SNS-101

VISTA
SOLID TUMORS
Preclinical

SNS-102

VSIG4
SOLID TUMORS
Discovery

SNS-103

ENTPDase1 / CD39
SOLID TUMORS
Discovery

ImmunoPhage™ Programs

The ImmunoPhage platform trains the immune system to react to cancer-specific antigens as if it were responding to a natural viral infection.

Program
Indication
Discovery
Preclinical
Phase I
Phase II

SNS-401-NG

MERKEL CELL CARCINOMA
Preclinical

SNS-401-NG

OTHER INDICATIONS
Discovery

HQ: 451 D St, Unit 710 , Boston, MA 02210

MD: 1405 Research Blvd, Suite 125,
Rockville, MD 20850